Immunovant Price PerformanceShares of IMVT stock traded up $0.21 on Friday, reaching $39.95. Following the completion of the sale, the chief executive officer owned 254,280 shares of the company’s stock, valued at approximately $9,784,694.40. Also, Director Atul Pande sold 1,500 shares of the company’s stock in a transaction dated Friday, June 26th. Institutional Trading of ImmunovantA number of hedge funds have recently bought and sold shares of the business. Nuveen LLC now owns 226,489 shares of the company’s stock worth $5,757,000 after purchasing an additional 1,449 shares during the last quarter.